|
1
|
Madias NE and Harrington JT: Platinum
nephrotoxicity. Am J Med. 65:307–314. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kintzel PE and Dorr RT: Anticancer drug
renal toxicity and elimination: Dosing guidelines for altered renal
function. Cancer Treat Rev. 21:33–64. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Filipski KK, Mathijssen RH, Mikkelsen TS,
Schinkel AH and Sparreboom A: Contribution of organic cation
transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin
Pharmacol Ther. 86:396–402. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nakamura T, Yonezawa A, Hashimoto S,
Katsura T and Inui K: Disruption of multidrug and toxin extrusion
MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem
Pharmacol. 80:1762–1767. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Moreno-Gordaliza E, Giesen C, Lázaro A,
Esteban-Fernández D, Humanes B, Cañas B, Panne U, Tejedor A,
Jakubowski N and Gómez-Gómez MM: Elemental bioimaging in kidney by
LA-ICP-MS as a tool to study nephrotoxicity and renal protective
strategies in cisplatin therapies. Anal Chem. 83:7933–7940. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kume M, Yasui H, Yoshikawa Y, Horinouchi
M, Higashiguchi K, Kobayashi Y, Kuroda D, Hirano T, Hirai M and
Nakamura T: Transient elevation of serum cystatin C concentrations
during perioperative cisplatin-based chemotherapy in esophageal
cancer patients. Cancer Chemother Pharmacol. 69:1537–1544. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Muñoz M, García-Erce JA and Remacha AF:
Disorders of iron metabolism. Part 1: Molecular basis of iron
homoeostasis. J Clin Pathol. 64:281–286. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chasapis CT, Loutsidou AC, Spiliopoulou CA
and Stefanidou ME: Zinc and human health: An update. Arch Toxicol.
86:521–534. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bost M, Houdart S, Oberli M, Kalonji E,
Huneau JF and Margaritis I: Dietary copper and human health:
Current evidence and unresolved issues. J Trace Elem Med Biol.
35:107–115. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cobanoglu U, Demir H, Sayir F, Duran M and
Mergan D: Some mineral, trace element and heavy metal
concentrations in lung cancer. Asian Pac J Cancer Prev.
11:1383–1388. 2010.PubMed/NCBI
|
|
11
|
Zowczak M, Iskra M, Torliński L and Cofta
S: Analysis of serum copper and zinc concentrations in cancer
patients. Biol Trace Elem Res. 82:1–8. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Díez M, Arroyo M, Cerdàn FJ, Muñoz M,
Martin MA and Balibrea JL: Serum and tissue trace metal levels in
lung cancer. Oncology. 46:230–234. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Issell BF, MacFadyen BV, Gum ET,
Valdivieso M, Dudrick SJ and Bodey GP: Serum zinc levels in lung
cancer patients. Cancer. 47:1845–1848. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sweeney JD, Ziegler P, Pruet C and
Spaulding MB: Hyperzincuria and hypozincemia in patients treated
with cisplatin. Cancer. 63:2093–2095. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang LS, Lin HY, Chang CJ, Fahn HJ, Huang
MH and Lin CF: Effects of en bloc esophagectomy on nutritional and
immune status in patients with esophageal carcinoma. J Surg Oncol.
67:90–98. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ganz T: Systemic iron homeostasis. Physiol
Rev. 93:1721–1741. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Akutsu Y, Kono T, Uesato M, Hoshino I,
Murakami K, Fujishiro T, Imanishi S, Endo S, Toyozumi T and
Matsubara H: Are additional trace elements necessary in total
parenteral nutrition for patients with esophageal cancer receiving
cisplatin-based chemotherapy? Biol Trace Elem Res. 150:109–115.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Filler G, Bökenkamp A, Hofmann W, Le
Bricon T, Martínez-Brú C and Grubb A: Cystatin C as a marker of
GFR-history, indications, and future research. Clin Biochem.
38:1–8. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Newman DJ: Cystatin C. Ann Clin Biochem.
39:89–104. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chew JS, Saleem M, Florkowski CM and
George PM: Cystatin C - a paradigm of evidence based laboratory
medicine. Clin Biochem Rev. 29:47–62. 2008.PubMed/NCBI
|
|
21
|
Oc MA, Demir H, Cekmen MB, Isgoren S,
Gorur GD and Bilgili U: Correlation of Cystatin-C and radionuclidic
measurement method of glomerular filtration rate in patients with
lung cancer receiving cisplatin treatment. Ren Fail. 36:1043–1050.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kos FT, Sendur MA, Aksoy S, Sezer S,
Civelek B, Yazici O, Yaman S, Eren T and Zengin N: Evaluation of
the renal function using cystatin C level in the patients receiving
cisplatin-based chemotherapy. Ren Fail. 35:705–710. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bodnar L, Wcislo GB, Smoter M,
Gasowska-Bodnar A, Stec R, Synowiec A and Szczylik C: Cystatin C as
a parameter of glomerular filtration rate in patients with ovarian
cancer. Kidney Blood Press Res. 33:360–367. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kris MG, Hesketh PJ, Somerfield MR, Feyer
P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ,
Gralla RJ, et al: American Society of Clinical Oncology: American
Society of Clinical Oncology guideline for antiemetics in oncology:
Update 2006. J Clin Oncol. 24:2932–2947. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bjarnadóttir M, Grubb A and Olafsson I:
Promoter-mediated, dexamethasone-induced increase in cystatin C
production by HeLa cells. Scand J Clin Lab Invest. 55:617–623.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yamawaki C, Takahashi M, Takara K, Kume M,
Hirai M, Yasui H and Nakamura T: Effect of dexamethasone on
extracellular secretion of cystatin C in cancer cell lines. Biomed
Rep. 1:115–118. 2013.PubMed/NCBI
|
|
27
|
Adamama-Moraitou KK, Saridomichelakis MN,
Polizopoulou Z, Kritsepi M, Tsompanakou A and Koutinas AF:
Short-term exogenous glucocorticosteroidal effect on iron and
copper status in canine leishmaniasis (Leishmania infantum). Can J
Vet Res. 69:287–292. 2005.PubMed/NCBI
|
|
28
|
Hodgkinson E, Neville-Webbe HL and Coleman
RE: Magnesium depletion in patients receiving cisplatin-based
chemotherapy. Clin Oncol (R Coll Radiol). 18:710–718. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Abbasciano V, Mazzotta D, Vecchiatti G,
Tassinari D, Nielsen I and Sartori S: Changes in serum,
erythrocyte, and urinary magnesium after a single dose of cisplatin
combination chemotherapy. Magnes Res. 4:123–125. 1991.PubMed/NCBI
|
|
30
|
Bodnar L, Wcislo G, Gasowska-Bodnar A,
Synowiec A, Szarlej-Wcisło K and Szczylik C: Renal protection with
magnesium subcarbonate and magnesium sulphate in patients with
epithelial ovarian cancer after cisplatin and paclitaxel
chemotherapy: A randomised phase II study. Eur J Cancer.
44:2608–2614. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yoshida T, Niho S, Toda M, Goto K, Yoh K,
Umemura S, Matsumoto S, Ohmatsu H and Ohe Y: Protective effect of
magnesium preloading on cisplatin-induced nephrotoxicity: A
retrospective study. Jpn J Clin Oncol. 44:346–354. 2014. View Article : Google Scholar : PubMed/NCBI
|
